Amgen Inc. $AMGN Shares Purchased by BXM Wealth LLC

BXM Wealth LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1,718.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,240 shares of the medical research company’s stock after acquiring an additional 25,742 shares during the quarter. BXM Wealth LLC’s holdings in Amgen were worth $8,916,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. West Family Investments Inc. increased its stake in shares of Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC lifted its stake in Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its stake in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after buying an additional 30 shares in the last quarter. Sittner & Nelson LLC grew its holdings in Amgen by 0.4% during the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after buying an additional 30 shares during the last quarter. Finally, ORG Partners LLC increased its position in Amgen by 0.6% during the fourth quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock worth $1,767,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMGN shares. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Jefferies Financial Group began coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective on the stock. Piper Sandler raised their target price on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Stock Performance

NASDAQ AMGN opened at $347.94 on Monday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market capitalization of $187.56 billion, a P/E ratio of 24.45, a P/E/G ratio of 3.45 and a beta of 0.47. The business’s 50-day simple moving average is $363.65 and its 200-day simple moving average is $333.18.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the company earned $5.31 EPS. The firm’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.